Airway administration of a highly versatile peptide-based liposomal construct for local and distant antitumoral vaccination

International Journal of Pharmaceutics

Volumn 496, Issue 2, 2015, Pages 1047-1056

  Kakhi, Zahra ^a   Frisch, Benoît ^a   Bourel Bonnet, Line ^a   Hemmerlé, Joseph ^b   Pons, Françoise ^a   Heurtault, Béatrice ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b Centre de Recherche en Biomédecine de Strasbourg   (France)

Author keywords

Cancer; Liposome; Mucosal immunization; Peptide based vaccine; Respiratory route; Vaccination

Indexed keywords

ADJUVANT; CANCER VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; GAMMA INTERFERON; INFLUENZA VIRUS HEMAGGLUTININ; INTERLEUKIN 6; LIPOSOME; NANOPARTICLE; TUMOR NECROSIS FACTOR ALPHA; ERBB2 PROTEIN, HUMAN; PEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNIZATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ADMINISTRATION ROUTE; EX VIVO STUDY; FEMALE; IMMUNE RESPONSE; IMMUNOGENICITY; KIDNEY CARCINOMA; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE ACTIVATION; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; BIOSYNTHESIS; BRONCHOALVEOLAR LAVAGE FLUID; IMMUNOLOGY; LUNG; VACCINATION;

ANIMALS; BRONCHOALVEOLAR LAVAGE FLUID; CANCER VACCINES; FEMALE; INTERFERON-GAMMA; LIPOSOMES; LUNG; MICE; MICE, INBRED BALB C; NANOPARTICLES; PEPTIDES; RECEPTOR, ERBB-2; VACCINATION;

EID: 84949627546     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2015.11.027     Document Type: Article

References (42)

1. M. Arjaans, O.M.T. Timmer-Bosscha, M. Reiss, A.M. Walenkamp, M.N. Lub-de Hooge, E.G. de Vries, and C.P. Schröder Transforming growth factor (TGF)-β expression and activation mechanisms as potential targets for anti-tumor therapy and tumor imaging Pharmacol. Ther. 135 2012 123 132
2. F. Azmi, A.A. Ahmad Fuaad, M. Skwarczynski, and I. Toth Recent progress in adjuvant discovery for peptide-based subunit vaccines Hum. Vaccin. Immunother. 10 2014 778 796
3. T. Boon, J.C. Cerottini, B. Van den Eynde, P. van der Bruggen, and A. Van Pel Tumor antigens recognized by T lymphocytes Annu. Rev. Immunol. 12 1994 337 365
4. H.M. Braakhuis, I. Gosens, P. Krystek, J.A. Boere, F.R. Cassee, P.H. Fokkens, J.A. Post, H. van Loveren, and M.V. Park Particle size dependent deposition and pulmonary inflammation after short-term inhalation of silver nanoparticles Particle Fibre Toxicol. 11 2014 49 63
5. L. Buonaguro, A. Petrizzo, M.L. Tornesello, and F.M. Buonaguro Translating tumor antigens into cancer vaccines Clin. Vaccine Immunol. 18 2011 23 34
6. D. Cipolla, B. Shekunov, J. Blanchard, and A. Hickey Lipid-based carriers for pulmonary products: preclinical development and case studies in humans Adv. Drug Deliv. Rev. 75 2014 53 80
7. J.F. Correia-Pinto, N. Csaba, and M.J. Alonso Vaccine delivery carriers: insights and future perspectives Int. J. Pharm. 440 2013 27 38
8. A.G. Dalgleish, and M.A. Whelan Cancer vaccines as a therapeutic modality: the long trek Cancer Immunol. Immunother. 55 2006 1025 1032
9. Z.G. Fridlender, and S.M. Albelda Tumor-associated neutrophils: friend or foe? Carcinogenesis 33 2012 949 955
10. M. Friede, M.H. Van Regenmortel, and F. Schuber Lyophilized liposomes as shelf items for the preparation of immunogenic liposome-peptide conjugates Anal. Biochem. 211 1993 117 122
11. H. Fujimoto, T. Sangai, G. Ishii, A. Ikehara, T. Nagashima, M. Miyazaki, and A. Ochiai Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression Int. J. Cancer 125 2009 1276 1284
12. S.I. Grivennikov, F.R. Greten, and M. Karin Immunity, inflammation and cancer Cell 140 2010 883 899
13. N.B. Hao, M.H. Lu, Y.H. Fan, Y.L. Cao, Z.R. Zhang, and S.M. Yang Macrophages in tumor microenvironments and the progression of tumors Clin. Dev. Immunol. 2012 948098 948109
14. A. Henderson, K. Propst, R. Kedl, and S. Dow Mucosal immunization with liposome-nucleic acid adjuvants generates effective humoral and cellular immunity Vaccine 29 2011 5304 5312
15. B. Heurtault, B. Frisch, and F. Pons Liposomes as delivery systems for nasal vaccination: strategies and outcomes Expert. Opin. Drug Deliv. 7 2010 829 844
16. B. Heurtault, P. Gentine, J.S. Thomann, C. Baehr, B. Frisch, and F. Pons Design of a liposomal candidate vaccine against Pseudomonas aeruginosa and its evaluation in triggering systemic and lung mucosal immunity Pharm. Res. 26 2009 276 285
17. H. Ikeda, L.J. Old, and R.D. Schreiber The roles of IFN gamma in protection against tumor development and cancer immunoediting Cytokine Growth Factor Rev. 13 2002 95 109
18. M.Z. Ladjemi, W. Jacot, T. Chardes, A. Pelegrin, and I. Navarro-Teulon Anti-HER2 vaccines: new prospects for breast cancer therapy Cancer Immunol. Immunother. 59 2010 1295 1312
19. W. Li, M. Joshi, S. Singhania, K. Ramsey, and A. Murthy Peptide vaccine: progress and challenges Vaccines 2 2014 515 536
20. + T-cell response using CpG oligodeoxynucleotides and HER-2/neu-derived peptide co-encapsulated in liposomes Vaccine 21 2003 3319 3329
21. B.E. Lippitz Cytokine patterns in patients with cancer: a systematic review Lancet Oncol. 14 2013 e218 e228
22. N. Lycke Recent progress in mucosal vaccine development: potential and limitations Nat. Rev. Immunol. 12 2012 592 605
23. A. Misra, K. Jinturkar, D. Patel, J. Lalani, and M. Chougule Recent advances in liposomal dry powder formulations: preparation and evaluation Expert Opin. Drug Deliv. 6 2009 71 89
24. T. Mocan The current status of human anti-cancer vaccines Biotechnol. Mol. Biol. Nanomed. 1 2013 1 7
25. A. Mukhopadhyay, C. Dyring, and D.I. Stott Comparison of prophylactic and therapeutic immunisation with an ErbB-2 (HER2) fusion protein and immunoglobulin V-gene repertoire analysis in a transgenic mouse model of spontaneous breast cancer Vaccine 32 2014 1012 1018
26. M.R. Neutra, and P.A. Kozlowski Mucosal vaccines: the promise and the challenge Nat. Rev. Immunol. 6 2006 148 158
27. G. Parmiani, C. Castelli, P. Dalerba, R. Mortarini, L. Rivoltini, F.M. Marincola, and A. Anichini Cancer immunotherapy with peptide-based vaccines: What have we achieved? - Where are we going J. Nat. Cancer I 94 2002 805 818
28. S.A. Perez, E. von Hofe, N.L. Kallinteris, A.D. Gritzapis, G.E. Peoples, M. Papamichail, and C.N. Baxevanis A new era in anticancer peptide vaccines Cancer 116 2010 2071 2080
29. D.D. Pham, E. Fattal, and N. Tsapis Pulmonary drug delivery systems for tuberculosis treatment Int. J. Pharm. 478 2015 517 529
30. K.K.L. Phua, H.F. Staats, K.W. Leong, and S.K. Nair Intranasal mRNA nanoparticle vaccination induces prophylactic and therapeutic anti-tumor immunity Sci. Rep. 4 2014 5128 5134
31. A. Roth, S. Espuelas, C. Thumann, B. Frisch, and F. Schuber Synthesis of thiol-reactive lipopeptide adjuvants. Incorporation into liposomes and study of their mitogenic effect on mouse splenocytes Bioconjug Chem. 15 2004 541 553
32. A. Roth, F. Rohrbach, R. Weth, B. Frisch, F. Schuber, and W.S. Wels Induction of effective and antigen-specific antitumour immunity by a liposomal ErbB2/HER2 peptide-based vaccination construct Br. J. Cancer 92 2005 1421 1429
33. A.D. Santin, S. Bellone, S. Van Stedum, W. Bushen, M. Palmieri, E.R. Siegel, L.E. De Las Casas, J.J. Roman, A. Burnett, and S. Pecorelli Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma Cancer 104 2005 1391 1397
34. P. Schelte, C. Boeckler, B. Frisch, and F. Schuber Differential reactivity of maleimide and bromoacetyl functions with thiols: application to the preparation of liposomal diepitope constructs Bioconjugate Chem. 11 2000 118 123
35. K. Schroder, P.J. Hertzog, T. Ravasi, and D.A. Hume Interferon-gamma: an overview of signals, mechanisms and functions J. Leukoc. Biol. 75 2004 163 189
36. J.-Y. Shih, A.Y. Jeremy, J.-W. Chen, and P.-C. Yang Tumor-associated macrophage: its role in cancer invasion and metastasis J. Cancer Mol. 2 2006 101 106
37. M. Skwarczynski, and I. Toth Recent advances in peptide-based subunit nanovaccines Nanomedicine (Lond.) 9 2014 2657 2669
38. C.L. Slingluff Jr. The present and future of peptide vaccines for cancer: single or multiple, long or short, alone or in combination? Cancer J. 17 2011 343 350
39. D.M. Smith, J.K. Simon, and J.R. Baker Applications of nanotechnology for immunology Nat. Rev. Immunol. 13 2013 592 605
40. J.S. Thomann, B. Heurtault, S. Weidner, M. Braye, J. Beyrath, S. Fournel, F. Schuber, and B. Frisch Antitumor activity of liposomal ErbB2/HER2 epitope peptide-based vaccine constructs incorporating TLR agonists and mannose receptor targeting Biomaterials 32 2011 4574 4583
41. N. Todorovic-Rakovic, and J. Milovanovic Interleukin-8 in breast cancer progression J. Interferon Cytokine Res. 2013 563 570
42. S. Zhou, S. Kawakami, F. Yamashita, and M. Hashida Intranasal administration of CpG DNA lipoplex prevents pulmonary metastasis in mice Cancer Lett. 287 2010 75 81